Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]
News [5245]
Articles [128]
Editorials [4]
Conferences [157]
elearning [13]
T cell therapy for ALL
Dr Max Topp - University of Wurzburg, Wurzburg, Germany
T cell therapy for ALL ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
11 Dec 2017
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma
Dr Michael Wang - MD Anderson Cancer Center, Houston, USA
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )
11 Dec 2017
Neuroblastoma and cell communication networks
Prof Walter Kolch - Systems Biology Ireland, UCD, Dublin, Ireland
Neuroblastoma and cell communication networks ( Prof Walter Kolch - Systems Biology Ireland, UCD, Dublin, Ireland )
11 Dec 2017
Shortening the time to manufacture CAR T-cells
Dr Partow Kebriaei - MD Anderson Center, Houston, USA
Shortening the time to manufacture CAR T-cells ( Dr Partow Kebriaei - MD Anderson Center, Houston, USA )
10 Dec 2017
Anti-BCMA CAR T cell therapy for multiple myeloma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Anti-BCMA CAR T cell therapy for multiple myeloma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
10 Dec 2017
Data from the CLARITY trial of ibrutinib plus venetoclax
Prof Peter Hillmen - University of Leeds, Leeds, UK
Data from the CLARITY trial of ibrutinib plus venetoclax ( Prof Peter Hillmen - University of Leeds, Leeds, UK )
10 Dec 2017
Mogamulizumab for cutaneous T- cell lymphoma
Prof Youn Kim - Stanford University, Stanford, CA
Mogamulizumab for cutaneous T- cell lymphoma ( Prof Youn Kim - Stanford University, Stanford, CA )
10 Dec 2017
Phase 1 study of Blu-285 in advanced systemic mastocytosis
Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA
Phase 1 study of Blu-285 in advanced systemic mastocytosis ( Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA )
10 Dec 2017
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial
Prof Peter Hillmen - University of Leeds, Leeds, UK
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial ( Prof Peter Hillmen - University of Leeds, Leeds, UK )
10 Dec 2017
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B...
Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma ( Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
10 Dec 2017
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study ( Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada )
10 Dec 2017
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's...
Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma ( Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada )
10 Dec 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation